News

MS Australia, together with Multiple Sclerosis organisations from Canada, Denmark, France, Germany, Italy, MS International Federation, Spain, U.K., and the U.S. have jointly declared their collective commitment to a global research strategy to cure MS.

MS Australia has today launched a new campaign at Parliament House on World MS Day (30 May) to raise awareness of the crucial role played by MS Nurses.

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the listing of natalizumab (Tysabri®) pre-filled syringe for subcutaneous (under the skin) injection on the Pharmaceutical Benefit Scheme (PBS).

CEO Rohan Greenland shares an update on The May 50K, thanking participants for their significant contributions. He then unveils MS Australia's plans to champion the invaluable role of MS Nurses on World MS Day.

Australian scientists have found new immune-suppressing molecules produced in response to UV exposure that may explain how UV protects from multiple sclerosis.

Clinical Trials Day is an opportunity to express our gratitude to the researchers, clinicians, and nurses who dedicate their lives to advancing medical knowledge and improving patient care. We thank them for their tireless efforts in conducting ground-breaking research and for their commitment to finding new and innovative treatments. Their work is essential for improving health outcomes for people around the world, and we are grateful for their dedication and contributions.

Developing and maintaining close friendships can be challenging for individuals with chronic conditions, like MS. Normative expectations about physical ability combined with the emotional and physical work required to maintain social connections can hinder the continuation of friendships.

Dr. Phu's MS Australia-funded research focuses on physiotherapy interventions to improve impaired functions caused by MS. His current project aims to develop personalised exercise programs with assistive devices to enhance walking abilities in people with MS. These advancements will be implemented at the new MS Plus Wellbeing Centres through Project Wellbeing.

The 2023-24 Federal Budget was delivered on 9 May 2023. MS Australia’s analysis of this Budget is through the lens of the two areas of fundamental need for people living with MS.

People with MS are helping us build the evidence for better government MS support.

CEO Rohan Greenland talks about the world's first multi-arm, multi-stage trial for progressive MS named 'OCTOPUS', which recently launched in the UK and the hope that in time Australia will be able to link up with this globally significant 'mega trial' with our own trial sites.

A new randomised controlled trial has found that people with neurological conditions (including MS) who receive a purposely designed internet-delivered psychological program, including cognitive behaviour therapy (CBT), report improvements in their depression, anxiety and functional disability levels.

Australian researchers have investigated the use of a sensitive measure of walking stability in people with MS at the early stages of disease.

Dr Ken Doyle has always been interested in cutting-edge research – but when it comes to MS, his interest is personal. Ken wants to fast-track a cure by ensuring MS research is appropriately funded.

MS Australia President, Associate Professor Des Graham, writes with multiple sclerosis increasing at a significant and accelerating rate, awareness and understanding of the often invisible disease is more important than ever.

The ‘What is MS?’ video attempts to demystify and explain a complex, and often at times, invisible disease that now impacts more than 33,000 Australians.

Australian researchers have investigated whether genetics and epigenetics contribute to the severity of MS.

Worse disease more likely for smokers, a new study finds.